Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Seegene, Inc.
  6. News
  7. Summary
    A096530   KR7096530001

SEEGENE, INC.

(A096530)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Seegene : Q2 2021 Earnings Show 11 Percent Revenue Growth, YoY

08/18/2021 | 06:01am EDT

-  Revenue of KRW 303.7 billion ($269.1 million) is record for second quarter, up 11 percent year-over-year

-  1H'21 Revenue at KRW 655.5 billion ($580.8 million), 58 percent achievement based on total sales in FY2020

-  Favorable market conditions expected in second half amid an increasing demand for COVID-19 tests due to the rapid spread of the Delta variant

SEOUL, South Korea, Aug. 18, 2021 /CNW/ -- Seegene Inc. (KQ 096530), a leading biotechnology company specializing in molecular diagnostics, today announced financial results for the second quarter ended June 30, 2021.

Logo (PRNewsfoto/Seegene Inc.)

Seegene reported KRW 303.7 billion ($269.1 million) in total sales, an 11% increase from the same period of the previous year. Operating profit slightly declined year-over-year to KRW 144.2 billion ($127.8 million) as the company has adopted various strategies for its long-term growth—including investments in R&D an recruiting talented personnel who majored in molecular diagnostics. Indeed, Seegene executed KRW 33.2 billion ($29.4 million) in R&D expenses in the 1H'21 alone, exceeding the previous year's total R&D expenses of KRW 26.2 billion ($23.2 million). Also, the number of employees tallied at 1008 as of June 2021, a 42% increase from the end of 2020.

However, the company posted solid revenue growth in the first half of 2021 at KRW 655.5 billion ($580.8 million), representing a whopping 84% growth from first half of 2020 and 58% achievement of the annual revenue of 2020. Although the company's sales in the second quarter rose year-over-year, it showed a 14% decline compared to the previous quarter. Seegene's official explained that the slight decline in revenue is largely due to the company's price policy that has been employed strategically to secure global market share. Also, as European nations have recently ramped up their drives on vaccination, it may have contributed to moderate slide in revenue.

Meanwhile, the company's outlook for the second half of the year looks relatively promising. Demand for COVID-19 test kits is on the rise thanks to the company's pricing policy and due to the emergence of highly transmissible COVID-19 variants such as the Delta variant. Besides, sales of non-COVID diagnostic reagents and other instruments are continuously increasing thereby the company's financial results will likely show a favorable performance in 2H21.

"Although the pandemic is still somewhat unpredictable, it is extremely crucial to conduct surveillance screenings as the virus continues to mutate. Our multiplex reagents are capable of detecting major COVID-19 variants in a single test while they are price competitive as well," said Myungkun Kim, Seegene's Senior Managing Director of IR and PR Department. "Also, as we are expanding our market in unexplored regions such as Asian and Latin American countries, we will be able to generate more valuable results in the global arena", he added.

KRW/USD= 1,128.55 (6/30/21) CER

Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/seegene-q2-2021-earnings-show-11-percent-revenue-growth-yoy-301357461.html

SOURCE Seegene Inc.

© Canada Newswire, source Canada Newswire English

All news about SEEGENE, INC.
09/28Seegene, Inc.'s Equity Buyback announced on March 9, 2021, has expired.
CI
09/27SEEGENE : Unveils Fully Automated Molecular Testing System at the 2021 AACC
AQ
09/27Seegene Inc. Unveils Fully Automated Molecular Testing System At the 2021 AACC
CI
09/01SEEGENE : Receives CE-IVD Mark for Use of Combo Swab, a Self-Collection Device with Four C..
AQ
08/18SEEGENE : Q2 2021 Earnings Show 11 Percent Revenue Growth, YoY
AQ
08/18Seegene Inc. Reports Earnings Results for the Second Quarter and First Half Ended June ..
CI
07/13SEEGENE : Introduces New SARS-CoV-2 Variants Detection Test That Can Screen Six Virus Vari..
AQ
07/13Seegene Introduces New SARS-CoV-2 Variants Detection Test That Can Screen Six Virus Var..
CI
07/06SEEGENE : announces partnership with Bio-Rad to develop diagnostic testing products for th..
AQ
07/02Tranche Update on Seegene, Inc.'s Equity Buyback Plan announced on March 9, 2021.
CI
More news
Financials
Sales 2021 1 221 B 1,04 B 1,04 B
Net income 2021 471 B 0,40 B 0,40 B
Net cash 2021 548 B 0,47 B 0,47 B
P/E ratio 2021 5,78x
Yield 2021 7,20%
Capitalization 2 699 B 2 295 M 2 299 M
EV / Sales 2021 1,76x
EV / Sales 2022 2,61x
Nbr of Employees 833
Free-Float 67,9%
Chart SEEGENE, INC.
Duration : Period :
Seegene, Inc. Technical Analysis Chart | A096530 | KR7096530001 | MarketScreener
Technical analysis trends SEEGENE, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 52 100,00 KRW
Average target price 84 500,00 KRW
Spread / Average Target 62,2%
EPS Revisions
Managers and Directors
Jong-Yoon Chun Chief Executive Officer & Director
Jung-Yong Kim Director & Head-Finance
Hong-Il Yoon Independent Director
Chang-Se Lee Independent Director
Kyung-Jun Chun Director
Sector and Competitors
1st jan.Capi. (M$)
SEEGENE, INC.-46.01%2 331
EXACT SCIENCES CORPORATION-27.67%16 596
GUARDANT HEALTH, INC.-18.48%10 642
INVITAE CORPORATION-31.81%6 196
BGI GENOMICS CO., LTD.-34.94%5 372
ADAPTIVE BIOTECHNOLOGIES CORPORATION-42.69%4 771